Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07181109 | Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease | PHASE3 | RECRUITING | 11,000 | — | — | Sep 22, 2025 | Sep 30, 2030 | May 14, 2026 | 742 | United States, Argentina +30 |
| Arm | Type | Description |
|---|---|---|
| Zilebesiran 300 mg | EXPERIMENTAL | Participants will be administered 300 mg zilebesiran subcutaneously (SC) once every 6 months as add-on therapy to their standard of care antihypertensive medications. |
| Placebo | PLACEBO_COMPARATOR | Participants will be administered placebo SC once every 6 months as add-on therapy to their standard of care antihypertensive medications. |
| Name | Type | Description |
|---|---|---|
| Zilebesiran | DRUG | Zilebesiran will be administered SC |
| Placebo | DRUG | Placebo will be administered SC |
Inclusion Criteria: * Is 18 years or older for patients with established cardiovascular disease (CVD) * Is 55 years or older for patients with high risk for CVD * Has established CVD (defined as coronary, cerebrovascular, or peripheral artery disease) or high risk for CVD * Has treated hypertension...